The study of cisplatin and vinorelbine in metastatic uterine cervical cancer
Kamnerdsupaphon, P.; Chitapanarux, I.; Tharavichitkul, E.; Sukthomya, V.; Lorvidhaya, V.
Journal of the Medical Association of Thailand 92(6): 836-840
2009
ISSN/ISBN: 0125-2208 PMID: 19530590 Document Number: 15613
To determine the therapeutic efficacy of cisplatin in combination with vinorelbine in the treatment of patients with metastatic cervical cancer. a total of 17 patients were enrolled in the present study. The median age was 46 years (38-65). There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment. The patients were planned to receive cisplatin 80 mg/m2 on day 1 and vinorelbine at 30 mg/m2 on day 1 and 8 every 3 weeks. Fifteen patients were available for evaluation: 2 (13.3%) achieved a complete response, 8 (53.4%) partial responses, 3 (20%) stable diseases and 2 (13.3%) progression of the disease. Myelosuppression was the major toxicity Grade 3-4 toxicities include 66.7% hemoglobin and 26.7% neutropenia. No other significant side effects were found. Cisplatin-vinorelbine is an active and well-tolerated regimen in metastatic cervical carcinoma. These results require confirmation.
Document emailed within 1 workday
